FISH – CLL PANEL Test Cost AED: 1900.0
Symptoms, Diagnosis, and Test Details
Test Name: FISH – CLL PANEL Test
Components: *del11q23(ATM), *del17p13.1(TP53), *del13q14.3, *del13q34, *trisomy 12, *IGH Gene breakapart
Price: 1900.0 AED
Sample Condition: 5 mL (3 mL min.) whole blood OR 4 mL (2 mL min.) Bone Marrow from 2 Green Top (Sodium Heparin) tubes. Ship at 18-22°C. DO NOT FREEZE. Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory.
Report Delivery: Sample Daily by 4 pm; Report 4 Working days
Method: FISH
Test type: Leukemia
Doctor: Oncologist, Hematologist
Test Department: CYTOGENETICS
Pre Test Information: Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory.
The FISH (Fluorescence In Situ Hybridization) – CLL (Chronic Lymphocytic Leukemia) Panel test is a genetic test used to detect specific genetic abnormalities in the chromosomes of cells from individuals with CLL.
Chronic Lymphocytic Leukemia is a type of cancer that affects the white blood cells, specifically the lymphocytes. The FISH – CLL Panel test helps to determine the prognosis and guide treatment decisions for individuals with CLL.
During the test, fluorescent probes are used to label specific regions of the chromosomes that are commonly affected in CLL. These probes bind to the targeted regions, allowing for visualization and analysis of any genetic abnormalities.
The FISH – CLL Panel test can detect abnormalities such as deletions or duplications in specific genes, such as the 17p deletion (TP53 gene) or 11q deletion (ATM gene), which are associated with a poorer prognosis in CLL.
The results of the FISH – CLL Panel test can help healthcare providers determine the best treatment options for individuals with CLL, as certain genetic abnormalities may indicate a higher likelihood of response to specific therapies.
It is important to note that the FISH – CLL Panel test is just one tool used in the diagnosis and management of CLL, and it is often performed in conjunction with other tests and assessments.
The test results should be interpreted by a qualified healthcare professional who specializes in hematologic malignancies.
Test Name | FISH – CLL PANEL Test |
---|---|
Components | *del11q23(ATM)*del17p13.1(TP53) *del13q14.3*del13q34*trisomy 12*IGH Gene breakapart |
Price | 1900.0 AED |
Sample Condition | 5 mL (3 mL min.) whole blood OR 4 mL ( 2 mL min.) Bone Marrow from 2 Green Top (Sodium Heparin) tubes. Ship at 18-22?\u00f8C. DO NOT FREEZE. Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory. |
Report Delivery | Sample Daily by 4 pm; Report 4 Working days |
Method | FISH |
Test type | Leukemia |
Doctor | Oncologist, Hematologist |
Test Department: | CYTOGENETICS |
Pre Test Information | Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory. |
Test Details |
The FISH (Fluorescence In Situ Hybridization) – CLL (Chronic Lymphocytic Leukemia) Panel test is a genetic test used to detect specific genetic abnormalities in the chromosomes of cells from individuals with CLL. Chronic Lymphocytic Leukemia is a type of cancer that affects the white blood cells, specifically the lymphocytes. The FISH – CLL Panel test helps to determine the prognosis and guide treatment decisions for individuals with CLL. During the test, fluorescent probes are used to label specific regions of the chromosomes that are commonly affected in CLL. These probes bind to the targeted regions, allowing for visualization and analysis of any genetic abnormalities. The FISH – CLL Panel test can detect abnormalities such as deletions or duplications in specific genes, such as the 17p deletion (TP53 gene) or 11q deletion (ATM gene), which are associated with a poorer prognosis in CLL. The results of the FISH – CLL Panel test can help healthcare providers determine the best treatment options for individuals with CLL, as certain genetic abnormalities may indicate a higher likelihood of response to specific therapies. It is important to note that the FISH – CLL Panel test is just one tool used in the diagnosis and management of CLL, and it is often performed in conjunction with other tests and assessments. The test results should be interpreted by a qualified healthcare professional who specializes in hematologic malignancies. |